Opendata, web and dolomites

TESTIMONY SIGNED

Tumor Endothelial Cells: Gatekeepers Of Anti-Tumor Immunity

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 TESTIMONY project word cloud

Explore the words cloud of the TESTIMONY project. It provides you a very rough idea of what is the project "TESTIMONY" about.

endothelial    therapy    effector    hematopoietic    transmigration    exceptional    anti    gap    immune    suffers    angiogenesis    immunosuppressive    resistance    goals    immunotherapy    least    upcoming    science    training    nutrients    cells    elevated    mice    knock    tec    career    tumor    unprecedented    inhibition    pd    vs    ecs    fractions    l1    levels    patients    innovative    expression    provides    lung    disciplinary    ec    immunosuppression    immunology    scientific    stimulate    form    dynamics    immunity    question    interactions    normal    tecs    attributable    line    effect    biology    cell    interface    relative    strategic    time    inhibitors    facilities    models    insights    stages    achievement    expressing    presumed    location    tumors    incompletely    fill    infrastructure    proliferation    efficacy    progression    delineate    raises    competitive    characterizing    human    core    expressed    expertise    lacking    host    vitro    cancer    successful    1st    blockade    checkpoint    function    combining    supply   

Project "TESTIMONY" data sheet

The following table provides information about the project.

Coordinator
VIB 

Organization address
address: RIJVISSCHESTRAAT 120
city: ZWIJNAARDE - GENT
postcode: 9052
website: www.vib.be

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Belgium [BE]
 Total cost 178˙320 €
 EC max contribution 178˙320 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2019
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2020
 Duration (year-month-day) from 2020-05-01   to  2022-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    VIB BE (ZWIJNAARDE - GENT) coordinator 178˙320.00

Map

 Project objective

Immunotherapy, in the form of immune checkpoint inhibitors, is the upcoming anti-cancer therapy, but suffers resistance in large fractions of cancer patients (also lung cancer). Tumors stimulate angiogenesis to ensure their supply of nutrients, however much less studied is how tumor endothelial cells (TECs) contribute to immunosuppression. Endothelial cells (ECs) represent a major non-hematopoietic component of immunity and TECs are presumed to be immunosuppressive, in part by expressing elevated levels of PD-L1. However, the role and dynamics of TEC-expressed PD-L1 in anti-tumor immunity relative to the cancer expressed PD-L1 remain incompletely understood.

Given the strategic “1st line” location of TECs, the question raises if at least part of the success of PD-L1 inhibition, is attributable to an effect on TEC immunity. Therefore, for the 1st time, I will fill this gap of knowledge by characterizing mice lacking PD-L1 in ECs and assess tumor progression and anti-tumor immunity in these mice using different tumor models. I will assess the efficacy of anti-PD-L1 blockade in mice lacking PD-L1 in ECs in different stages of tumor growth to delineate the dynamics of PD-L1 expression in TECs. Moreover, by using established in vitro approaches, I will study the effect of PD-L1 knock-down in human lung tumor derived TECs vs. normal ECs on human T cell proliferation, effector function and transmigration. The proposed research provides unprecedented insights in the relative role of tumor endothelial vs. cancer cell-derived PD-L1 in immunosuppression.

This is a multi-disciplinary project at the interface of angiogenesis, immunology and cancer. Combining my expertise on T cell biology with the host’s expertise in angiogenesis and exceptional scientific infrastructure (core facilities) and innovative science (EC:T cell interactions during immunotherapy) will ensure successful achievement of the project goals and provide a highly competitive training for my future career.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TESTIMONY" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "TESTIMONY" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

NaWaTL (2020)

Narrative, Writing, and the Teotihuacan Language: Exploring Language History Through Phylogenetics, Epigraphy and Iconography

Read More  

MingleIFT (2020)

Multi-color and single-molecule fluorescence imaging of intraflagellar transport in the phasmid chemosensory cilia of C. Elegans

Read More  

EPIC (2019)

Evolution of Planktonic Gastropod Calcification

Read More